Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Intratumoral heterogeneity impacts the response to anti-neu antibody therapy.

Song H, Kim TO, Ma SY, Park JH, Choi JH, Kim JH, Kang MS, Bae SK, Kim KH, Kim TH, Seo SK, Choi IW, Song GA, Mortenson ED, Fu YX, Park S.

BMC Cancer. 2014 Sep 1;14:647. doi: 10.1186/1471-2407-14-647.

2.

Recipient NK cell inactivation and intestinal barrier loss are required for MHC-matched graft-versus-host disease.

Nalle SC, Kwak HA, Edelblum KL, Joseph NE, Singh G, Khramtsova GF, Mortenson ED, Savage PA, Turner JR.

Sci Transl Med. 2014 Jul 2;6(243):243ra87. doi: 10.1126/scitranslmed.3008941.

3.

Anti-HER2/Neu passive-aggressive immunotherapy.

Mortenson ED, Fu YX.

Oncoimmunology. 2014 Jan 1;3(1):e27296.

4.

Adaptive Immune Responses and HER2/neu Positive Breast Cancer.

Mortenson ED, Fu YX.

Curr Pathobiol Rep. 2013 Mar;1(1):37-42.

5.

Effective anti-neu-initiated antitumor responses require the complex role of CD4+ T cells.

Mortenson ED, Park S, Jiang Z, Wang S, Fu YX.

Clin Cancer Res. 2013 Mar 15;19(6):1476-86. doi: 10.1158/1078-0432.CCR-12-2522. Epub 2013 Jan 30.

6.

Cetuximab-mediated tumor regression depends on innate and adaptive immune responses.

Yang X, Zhang X, Mortenson ED, Radkevich-Brown O, Wang Y, Fu YX.

Mol Ther. 2013 Jan;21(1):91-100. doi: 10.1038/mt.2012.184. Epub 2012 Sep 18.

7.

Targeting and utilizing primary tumors as live vaccines: changing strategies.

Yang X, Mortenson ED, Fu YX.

Cell Mol Immunol. 2012 Jan;9(1):20-6. doi: 10.1038/cmi.2011.49. Epub 2011 Nov 21. Review.

8.

The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity.

Park S, Jiang Z, Mortenson ED, Deng L, Radkevich-Brown O, Yang X, Sattar H, Wang Y, Brown NK, Greene M, Liu Y, Tang J, Wang S, Fu YX.

Cancer Cell. 2010 Aug 9;18(2):160-70. doi: 10.1016/j.ccr.2010.06.014.

Supplemental Content

Loading ...
Support Center